Get the Stockscreener App
14.88
2.87%
-0.44
After Hours:
14.88
Spyre Therapeutics Inc stock is traded at $14.88, with a volume of 967.95K.
It is down -2.87% in the last 24 hours and down -7.64% over the past month.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
See More
Previous Close:
$15.32
Open:
$15.46
24h Volume:
967.95K
Relative Volume:
1.71
Market Cap:
$898.77M
Revenue:
$688.00K
Net Income/Loss:
$-170.19M
P/E Ratio:
-5.027
EPS:
-2.96
Net Cash Flow:
$-154.68M
1W Performance:
-4.92%
1M Performance:
-7.64%
6M Performance:
-19.13%
1Y Performance:
-51.05%
1-Day Range:
$14.63
$15.46
1-Week Range:
$14.63
$15.84
52-Week Range:
$10.91
$40.26
Spyre Therapeutics Inc Stock (SYRE) Company Profile
Name
Spyre Therapeutics Inc
Sector
Industry
Phone
(617) 651-5940
Address
221 CRESCENT STREET, WALTHAM
Compare SYRE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
14.88 | 925.34M | 688.00K | -170.19M | -154.68M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
383.12 | 99.25B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.99 | 63.46B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.56 | 59.27B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
736.76 | 44.78B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
334.40 | 37.75B | 3.81B | -644.79M | -669.77M | -6.24 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-08-25 | Initiated | Leerink Partners | Outperform |
| Mar-18-25 | Initiated | Wolfe Research | Outperform |
| Sep-04-24 | Initiated | Wedbush | Outperform |
| Jul-16-24 | Initiated | Evercore ISI | Outperform |
| May-02-24 | Initiated | Robert W. Baird | Outperform |
| Mar-01-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-20-23 | Initiated | BTIG Research | Buy |
| Dec-11-23 | Initiated | Guggenheim | Buy |
| Dec-11-23 | Initiated | Jefferies | Buy |
| May-04-20 | Initiated | Piper Sandler | Overweight |
| Mar-21-19 | Initiated | JP Morgan | Overweight |
| Sep-04-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Apr-24-18 | Initiated | Evercore ISI | Outperform |
| Mar-14-18 | Reiterated | Needham | Buy |
View All
Spyre Therapeutics Inc Stock (SYRE) Latest News
Goldman Sachs Group Inc. Reduces Stake in Spyre Therapeutics, Inc. $SYRE - Defense World
Chart overlay techniques for tracking Spyre Therapeutics Inc.Stop Loss & Fast Gaining Stock Strategy Reports - newser.com
Spyre Therapeutics (NASDAQ:SYRE) Stock Rating Lowered by Wall Street Zen - MarketBeat
Tools to monitor Spyre Therapeutics Inc. recovery probabilityPortfolio Value Report & Daily Technical Stock Forecast Reports - newser.com
Published on: 2025-09-20 10:39:32 - khodrobank.com
What does recent volatility data suggest for Spyre Therapeutics Inc.Quarterly Profit Report & Free Technical Pattern Based Buy Signals - newser.com
Published on: 2025-09-19 15:19:15 - newser.com
Does Spyre Therapeutics Inc. qualify in momentum factor screeningWeekly Trading Summary & Fast Gaining Stock Reports - newser.com
CEO Change: Is Spyre Therapeutics Inc. gaining market share2025 Biggest Moves & Daily Profit Maximizing Tips - khodrobank.com
Spyre Therapeutics (NASDAQ:SYRE) Trading Down 4.6%Time to Sell? - MarketBeat
Update Report: What’s the RSI of Spyre Therapeutics Inc. stock2025 Macro Impact & Entry Point Confirmation Alerts - khodrobank.com
How to use a screener to detect Spyre Therapeutics Inc. breakoutsWeekly Investment Report & Fast Momentum Entry Tips - newser.com
Short Squeeze: How does Spyre Therapeutics Inc score in quality rankingsDay Trade & Smart Swing Trading Alerts - khodrobank.com
Intelligent Development Could Make Spyre Therapeutics Best In Show - Seeking Alpha
Using fundamentals and technicals on Spyre Therapeutics Inc.Weekly Gains Summary & Weekly Breakout Stock Alerts - newser.com
Why Spyre Therapeutics Inc. is moving todayMarket Movers & Fast Gain Swing Trade Alerts - newser.com
BTIG Research Reaffirms Buy Rating for Spyre Therapeutics (NASDAQ:SYRE) - MarketBeat
Woodline Partners LP Boosts Position in Spyre Therapeutics, Inc. $SYRE - MarketBeat
Can Spyre Therapeutics Inc maintain sales growthJuly 2025 Recap & Community Verified Swing Trade Signals - khodrobank.com
Published on: 2025-09-16 12:08:18 - newser.com
US Market Recap: Is Spyre Therapeutics Inc stock good for income investors2025 AllTime Highs & Weekly High Return Stock Opportunities - khodrobank.com
Energy Moves: Will Spyre Therapeutics Inc benefit from current market trends2025 Market WrapUp & Reliable Volume Spike Alerts - khodrobank.com
Spyre Therapeutics (SYRE): Analyst Reiterates Buy Rating | SYRE Stock News - GuruFocus
Can you recover from losses in Spyre Therapeutics Inc.Quarterly Profit Review & Capital Efficiency Focused Strategies - newser.com
Pullback Watch: Will Spyre Therapeutics Inc benefit from government policy2025 Biggest Moves & High Yield Equity Trading Tips - khodrobank.com
Support Test: Is Spyre Therapeutics Inc benefiting from interest rate changesQuarterly Portfolio Report & Fast Moving Stock Trade Plans - خودرو بانک
Growth Recap: Is Spyre Therapeutics Inc stock good for income investorsJuly 2025 Selloffs & Free Weekly Chart Analysis and Trade Guides - khodrobank.com
Value Recap: Is Spyre Therapeutics Inc a top pick in the sectorJuly 2025 Trends & Weekly Consistent Profit Watchlists - خودرو بانک
Is Spyre Therapeutics Inc. stock bottoming out2025 Bull vs Bear & Smart Money Movement Tracker - newser.com
History Review: What are Spyre Therapeutics Inc.’s growth leversJuly 2025 Movers & AI Enhanced Execution Alerts - خودرو بانک
What Fibonacci levels say about Spyre Therapeutics Inc. reboundBull Run & Fast Exit/Entry Strategy Plans - newser.com
Spyre Therapeutics (SYRE) Doses First Patient In Promising SPY072 Phase 2 Trial - Yahoo Finance
Spyre Therapeutics doses first patient in phase 2 rheumatic disease trial - Investing.com
Spyre Flat on Test Result - Baystreet.ca
Spyre Therapeutics doses first patient in phase 2 rheumatic disease trial By Investing.com - Investing.com South Africa
Spyre doses first patient in phase 2 SKYWAY trial of SPY072, first anti-TL1A antibody for rheumatic diseases - MarketScreener
First-Ever Anti-TL1A Drug for 3M+ Rheumatic Patients: Spyre's SPY072 Enters Phase 2 Trial - Stock Titan
Detecting support and resistance levels for Spyre Therapeutics Inc.July 2025 Gainers & Technical Pattern Based Buy Signals - newser.com
Automated trading signals detected on Spyre Therapeutics Inc.2025 Institutional Moves & Weekly Chart Analysis and Guides - newser.com
Spyre Therapeutics Inc Stock (SYRE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.43%
0.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):